# The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations

> **NCT02855047** · — · COMPLETED · sponsor: **Centre Hospitalier Universitaire de Nīmes** · enrollment: 513 (actual)

## Conditions studied

- Antiphospholipid Syndrome

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02855047
- **Lead sponsor:** Centre Hospitalier Universitaire de Nīmes
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2016-12-31
- **Final completion:** 2016-12-31
- **Target enrollment:** 513 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02855047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02855047, "The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02855047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*